PROCEPT BioRobotics (PROCEPT BioRobotics) ROCE % : -28.35% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is PROCEPT BioRobotics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PROCEPT BioRobotics's annualized ROCE % for the quarter that ended in Mar. 2024 was -28.35%.

PROCEPT BioRobotics ROCE % Historical Data

The historical data trend for PROCEPT BioRobotics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROCEPT BioRobotics ROCE % Chart

PROCEPT BioRobotics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-74.72

-57.32

-25.01

-27.56

-32.21

PROCEPT BioRobotics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial												-41.97	-39.83	-30.64	-28.57	-28.35

PROCEPT BioRobotics ROCE % Calculation

PROCEPT BioRobotics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-101.902	/	( ( (309.329 - 35.29)	+	(404.717 - 45.927) )	/ 2 )
	=	-101.902	/	( (274.039	+	358.79)	/ 2 )
	=	-101.902	/	316.4145
	=	-32.21 %

PROCEPT BioRobotics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-99.648	/	( ( (404.717 - 45.927)	+	(382.9 - 38.65) )	/ 2 )
	=	-99.648	/	( ( 358.79	+	344.25 )	/ 2 )
	=	-99.648	/	351.52
	=	-28.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

PROCEPT BioRobotics (NAS:PRCT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PROCEPT BioRobotics ROCE % Related Terms

Thank you for viewing the detailed overview of PROCEPT BioRobotics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PROCEPT BioRobotics Corp (NAS:PRCT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Island Drive, Redwood, CA, USA, 94065

Website

https://www.procept-biorobotics.com

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Executives

Alaleh Nouri	officer: SVP, GEN COUNSEL, CORP. SEC.	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Kevin Waters	officer: Senior VP, CFO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Frederic H Moll	director	C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Wood Morgan Colby	director	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065
Reza Zadno	director, officer: President, CEO	2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Hisham Shiblaq	officer: SVP, Commercial Operations	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Thomas M Krummel	director	C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 88 Llc	10 percent owner	55 RAILROAD AVE, GREENWICH CT 06830
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901